TR-Dizin İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/9
Browse
3 results
Search Results
Article Post Challenge Effects of Ozg-38.61.3 Gamma Irradiated SARS-CoV Vaccine on Organ Protection in Transgenic Mouse Model(Marmara University, Institute of Health Sciences, 2025) Telci, Dilek; Akpınar, Gürler; Tuğlu, Mehmet İbrahim; Ovalı, Ercüment; Oztatlıcı, Hulya; Şahin, Fikrettin; Demir, Sevda; Kancagi, Derya Dilek; Turan, Raife Dilek; Oztatlici, Mustafa; Karakus, Gozde Sir; Yurtsever, BulutObjective: Coronavirus disease 2019 (COVID-19) is an infectious outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) and virus-related deaths are increasing day by day. For this reason, vaccine studies and their urgent use are of great importance to prevent the pandemic. In this study, multi-organ damages caused by SARS-CoV-2 virus in human- angiotensin-converting enzyme type 2 (ACE2) transgenic mice and the protective effects of OZG-38.61.3 gamma irradiated SARS-CoV-2 vaccine against viral damage were investigated. Methods: For this purpose, transgenic K18-hACE2 BALB/c mice were randomly allocated into 4 groups, negative control group (NC), positive control group (PC, SARS-CoV-2 infected), and 2 different doses of OZG-38.61.3 vaccine (Challenge 1, dose of 10 13 and Ch2, 10 14 viral particle after SARS-CoV-2 infection). After the administrations, lung, heart and kidney tissues were examined by histopathological, immunohistochemical and TUNEL analysis. Results: Our results showed that the vaccine doses decreased the apoptosis, oxidative stress and inflammation parameters caused by virus in lung, heart, and kidney tissues. It was also found that the vaccine protected the expressions of tight junction proteins in the kidneys. Conclusion: According to our findings, it is suggested that the OZG-38.61.3 can be an effective and protective vaccine that can be safely used against the SARS-CoV-2 virus.Article Canlı Vericili Karaciğer Naklinde Retrospektif Donör Hepatektomi Sonuçları- Tek Merkezdeneyimi(2021) Andaçoğlu, Oya M.; Dönmez, RamazanAmaç: Donör hepatektomi tekniğimizi ve donör seçimimizi tanımlamayı, vaka serimizi gözden geçirmeyi, \rkomplikasyon oranlarımızı ve sonuçlarımızı bildirmeyi amaçladık. \rGereç ve Yöntemler: Yeditepe Üniversite Hastanesi'nde Ekim 2019- Kasım 2020 tarihleri arasında 41 ardışık \rdonör hepatektomi olgusunu retrospektif olarak inceledik. Komplikasyonlar Clavien-Dindo sınıflamasına göre \rderecelendirildi. Tüm olgular laparotomi ile yapıldı. \rBulgular: 41 donör olgusunun 38'i (%92,6) sağ lob, 2'si (%4,8) sol lob ve 1'i (%2,4) sol lateral segment donör \rhepatektomisi idi. Takip süresi 9 ± 2,2 aydı (4-16 ay). Sekiz (%19,5) komplikasyon vardı ve hepsi minördü \r(derece 1 veya 2). Derece 3 veya daha yüksek komplikasyon görülmedi. Üç donörde heterozigot Faktör 5 \rLeiden mutasyonu ve 4 tanesinde heterozigot protrombin mutasyonu vardı. Kalış süresi ortalama 6,4±1,4 gündü \r(aralık = 5-12). Kontrollü diyet ve egzersiz programı ile 10 donör kilo verdi. Bu hasta alt grubunda bir yara \rkomplikasyonu vardı. \rSonuç: Tek merkezli donör hepatektomi serimizi çok iyi sonuçlarla sunuyoruz. Ayrıca Vücut Kitle İndeksi > 30\rkg/m2\rolan donörler için başarılı kilo vermeyi de tanımlıyoruz. Donör güvenliği, canlı donör karaciğer naklinin \ren önemli bileşenidir. Donör sonuçları iyi oldukça, canlı vericili karaciğer nakli dünya çapında yaygınlaşmaya \rdevam edecektir.\rArticle Acute Serious Hepatitis of Unknown Cause in Children(Galenos Publishing House, 2022) Kılbaş, E.P.K.; Altındiş, M.On April 5, 2022, an increase in cases of acute hepatitis of unknown etiology was reported in previously healthy children under the age of 10 in the United Kingdom. Since there is no link between these patients, called acute non-HepA-E hepatitis, and viral hepatitis agents (hepatitis A, B, C, D, and E), the possible etiology, and pathogenesis of this emergency is being investigated. One of the alarming features of this epidemic is the high requirement for liver transplantation in a fraction of the cases. In cases other than hepatitis A, B, C, D, and E, a case definition is made by looking at a series of clinical pictures, including serum transaminase levels and age. As of August 26, 2022, 513 cases of acute hepatitis have been reported in Europe and 1,010 globally. Adenovirus was detected in 75% of cases tested in the UK, but data for other countries are still lacking. The role of other etiologic agents is still under investigation. The exact disease pathogenesis has not yet clear. Evidence of human-to-human transmission of the disease remains unclear. Epidemiological studies are critical in clarifying the uncertainties regarding the existence of links between the cases reported to date. Continuing the national and international surveillance activities of the countries in an organized manner is the most basic issue required for the elimination of the epidemic. Copyright © 2022 Tehran University of Medical Sciences.